No Prescription |
 |
 | ||
|
PURINETHOL Generic Mercaptopurine |
|
| ||
No Prescription » Prescription Drugs 13 » PURINETHOL Generic Mercaptopurine Product Origin: EU (Turkey)This product is able to be sourced and supplied at excellent prices because of favourable cross border currency conversions. All products are authentic brand names and will include a product information insert in English.Medical Information:Mercaptopurine (mer-kap-toe-PYOOR-een) belongs to the group of medicines known as antimetabolites. It is used to treat some kinds of cancer. Mercaptopurine is a cancer medication that interferes with the growth of cancer cells and slows their growth and spread in the body.Mercaptopurine is used to treat acute lymphatic leukemia or acute myelogenous leukemia. Mercaptopurine is usually given together with other cancer medications Buy PURINETHOL Generic Mercaptopurine and other Prescription Drugs 13 products online at Medstore. 3611
About PURINETHOL Generic Mercaptopurine: Product Type: Prescription Drugs 13 PURINETHOL ( Generic Mercaptopurine ) PURINETHOL (Generic Mercaptopurine) Generic Mercaptopurine 50mg 25 Tabs Generic Mercaptopurine PURINETHOL
View more Prescription Drugs 13 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
